Develops therapies targeting the underlying causes of chronic inflammatory and autoimmune diseases, such as primary HLH and Adult-onset Still's Disease, by inhibiting IL-18 signaling. Its lead candidate, Tadekinig alfa, has demonstrated a favorable safety profile in Phase I, Ib, and II trials and is currently undergoing pivotal Phase 3 trials for monogenic HLH.
Funding
$57.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic inflammatory and autoimmune diseases, such as primary hemophagocytic lymphohistiocytosis (HLH) and Adult-onset Still's Disease, are driven by dysregulated inflammatory processes, resulting in significant unmet medical needs. Current treatments often address symptoms without targeting the underlying causes of these diseases.
Solution
AB2 Bio is developing targeted therapies that address the root causes of chronic inflammatory and autoimmune diseases by inhibiting interleukin-18 (IL-18) signaling. Their lead candidate, Tadekinig alfa, is designed to modulate the inflammatory response, offering a potential disease-modifying approach. Tadekinig alfa has demonstrated a favorable safety profile in Phase I, Ib, and II clinical trials. The company is focusing on advancing clinical programs for primary HLH, including NLRC4 mutation and XIAP deficiency, as well as Adult-onset Still's Disease.
Target Audience
The primary target audience includes patients suffering from chronic inflammatory and autoimmune diseases with large unmet medical needs, such as primary HLH and Adult-onset Still's Disease, and the physicians who treat them.
Features
- Tadekinig alfa: A targeted therapy inhibiting IL-18 signaling to address the underlying causes of inflammation-based diseases.
- Demonstrated high tolerance and excellent safety profile in Phase I, Ib, and II clinical trials.
- Advanced clinical programs in primary HLH (NLRC4 mutation and XIAP deficiency) and Adult-onset Still’s Disease.